Exane BNP Paribas Reconfirmed AstraZeneca (LON:AZN) As a “Outperform”; They Now Have a Target Of GBX 5500

Share

AstraZeneca (LON:AZN) Rating Reaffirmed

Exane BNP Paribas now has a GBX 5500 Estimated Target Price on shares of AstraZeneca (LON:AZN). The Estimated Target Price would indicate a potential upside of 22.28% from the current stock price of AstraZeneca (LON:AZN). This rating was revealed to clients and investors in an analyst note on 8 December.

From a total of 29 analysts covering AstraZeneca PLC (LON:AZN) stock, 18 rate it a ”Buy”, 6 a “Sell”, and 10 a ”Hold”. This means that 53% of the ratings are positive. The highest target price is GBX 95.19 while the lowest target price is GBX 36. The mean of all analyst targets is GBX 71.21 with a 7.68% above today’s (GBX 4480) stock price. AstraZeneca PLC was the topic of 120 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. BNP Paribas maintained shares on December 7 with “Outperform” rating. UBS maintained shares with “Buy” rating and GBX 5000 target share price in a report from a November 25. Handelsbanken maintained AZN stock in a recent report from December 4 with “Accumulate” rating. Credit Suisse maintained the rating on November 24. Credit Suisse has a “Underperform” rating and a GBX 4000 price target on shares. Finally, Bernstein maintained the stock with “Market Perform” rating in a report issued on a December 1.

Approximately 518,230 shares of stock traded hands. AstraZeneca plc (LON:AZN) has declined 0.98% since May 11, 2015 and is downtrending. It has underperformed by 0.39% the S&P500.

Exane BNP Paribas Reconfirmed AstraZeneca (LON:AZN) As a

AstraZeneca PLC is a global biopharmaceutical company. The company has a market cap of 55.89 billion GBP. The Firm discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. It has 50.62 P/E ratio. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.” Get a free copy of the Zacks research report on AstraZeneca plc (AZN).

COMMENTS: